These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31527169)

  • 1. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
    Froeling FEM; Swamynathan MM; Deschênes A; Chio IIC; Brosnan E; Yao MA; Alagesan P; Lucito M; Li J; Chang AY; Trotman LC; Belleau P; Park Y; Rogoff HA; Watson JD; Tuveson DA
    Clin Cancer Res; 2019 Dec; 25(23):7162-7174. PubMed ID: 31527169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
    Shao Z; Wang H; Ren H; Sun Y; Chen X
    Molecules; 2023 Jul; 28(15):. PubMed ID: 37570646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
    Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
    Cancer; 2020 Jul; 126(14):3360-3371. PubMed ID: 32383803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
    Chang AY; Hsu E; Patel J; Li Y; Zhang M; Iguchi H; Rogoff HA
    Mol Cancer Res; 2019 Jul; 17(7):1429-1434. PubMed ID: 31043490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
    Löcken H; Clamor C; Müller K
    J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
    Hanafi M; Chen X; Neamati N
    J Med Chem; 2021 Feb; 64(3):1626-1648. PubMed ID: 33506674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
    Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA
    Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
    Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
    Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
    J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
    Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
    Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
    Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
    Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
    Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
    Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
    Han D; Yu T; Dong N; Wang B; Sun F; Jiang D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
    Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facilitation of 9,10-phenanthrenequinone-elicited neuroblastoma cell apoptosis by NAD(P)H:quinone oxidoreductase 1.
    Matsunaga T; Kamase K; Takasawa H; Yamaji Y; Endo S; El-Kabbani O; Ikari A
    Chem Biol Interact; 2018 Jan; 279():10-20. PubMed ID: 29108775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isopentyl-Deoxynboquinone Induces Mitochondrial Dysfunction and G2/M Phase Cell Cycle Arrest to Selectively Kill
    Jiang L; Liu Y; Tumbath S; Boudreau MW; Chatkewitz LE; Wang J; Su X; Zahid KR; Li K; Chen Y; Yang K; Hergenrother PJ; Huang X
    Antioxid Redox Signal; 2024 Jul; 41(1-3):74-92. PubMed ID: 37950707
    [No Abstract]   [Full Text] [Related]  

  • 17. Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer.
    Pathania D; Sechi M; Palomba M; Sanna V; Berrettini F; Sias A; Taheri L; Neamati N
    Biochim Biophys Acta; 2014 Jan; 1840(1):332-43. PubMed ID: 23954204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
    Li X; Wei Y; Wei X
    Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
    Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
    Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of salt-induced renal injury by activation of NAD(P)H:quinone oxidoreductase 1, associated with NADPH oxidase.
    Kim YH; Hwang JH; Noh JR; Gang GT; Tadi S; Yim YH; Jeoung NH; Kwak TH; Lee SH; Kweon GR; Kim JM; Shong M; Lee IK; Lee CH
    Free Radic Biol Med; 2012 Mar; 52(5):880-8. PubMed ID: 22227174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.